Heparin Oligosaccharides As Potential Therapeutic Agents in Senile Dementia

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2007 May 17

PMID 17504153

Citations 13

Authors

Qing Ma

Umberto Cornelli

Israel Hanin

Walter P Jeske

Robert J Linhardt

Jeanine M Walenga

Jawed Fareed

John M Lee

Affiliations

Soon will be listed here.

Abstract

Heparin is a glycosaminoglycan mixture currently used in prophylaxis and treatment of thrombosis. Heparin possesses non-anticoagulant properties, including modulation of various proteases, interactions with fibroblast growth factors, and anti-inflammatory actions. Senile dementia of Alzheimer's type is accompanied by inflammatory responses contributing to irreversible changes in neuronal viability and brain function. Vascular factors are also involved in the pathogenesis of senile dementia. Inflammation, endogenous proteoglycans, and assembly of senile plagues and neurofibrillary tangles contribute directly and indirectly to further neuronal damage. Neuron salvage can be achieved by anti-inflammation and the competitive inhibition of proteoglycans accumulation. The complexity of the pathology of senile dementia provides numerous potential targets for therapeutic interventions designed to modulate inflammation and proteoglycan assembly. Heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents.

Citing Articles

Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy.

Sultana R, Kamihira M Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459002 PMC: 11510354. DOI: 10.3390/ph17101362.

Biological Properties of Heparins Modified with an Arylazopyrazole-Based Photoswitch.

Stolarek M, Pycior A, Bonarek P, Opydo M, Kolaczkowska E, Kaminski K J Med Chem. 2023; 66(3):1778-1789.

PMID: 36657057 PMC: 9923745. DOI: 10.1021/acs.jmedchem.2c01616.

Metal Binding to Sodium Heparin Monitored by Quadrupolar NMR.

Sieme D, Griesinger C, Rezaei-Ghaleh N Int J Mol Sci. 2022; 23(21).

PMID: 36361973 PMC: 9655979. DOI: 10.3390/ijms232113185.

Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics.

OSullivan J, Munoz-Munoz J, Turnbull G, Sim N, Penny S, Moschos S RSC Adv. 2022; 12(32):20432-20446.

PMID: 35919168 PMC: 9281799. DOI: 10.1039/d2ra01999j.

Heparin-Assisted Amyloidogenesis Uncovered through Molecular Dynamics Simulations.

Khurshid B, Rehman A, Luo R, Khan A, Wadood A, Anwar J ACS Omega. 2022; 7(17):15132-15144.

PMID: 35572757 PMC: 9089684. DOI: 10.1021/acsomega.2c01034.

References

Highsmith R, Rosenberg R . The inhibition of human plasmin by human antithrombin-heparin cofactor. J Biol Chem. 1974; 249(14):4335-8. View

Lindahl B, Westling C, Gimenez-Gallego G, Lindahl U, Salmivirta M . Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J Biol Chem. 1999; 274(43):30631-5. DOI: 10.1074/jbc.274.43.30631. View

Gollin P, Kalaria R, Eikelenboom P, Rozemuller A, Perry G . Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport. 1992; 3(2):201-3. DOI: 10.1097/00001756-199202000-00020. View

Glenner G, Wong C . Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984; 120(3):885-90. DOI: 10.1016/s0006-291x(84)80190-4. View

Janciauskiene S, Sun Y, Wright H . Interactions of A beta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer's disease. Neurobiol Dis. 2002; 10(3):187-200. DOI: 10.1006/nbdi.2002.0519. View

TYRRELL D, Horne A, Holme K, Preuss J, Page C . Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol. 1999; 46:151-208. DOI: 10.1016/s1054-3589(08)60471-8. View

Fareed J, Hoppensteadt D . Heparins in the new millennium: will unfractionated heparin survive? Epilogue. Semin Thromb Hemost. 2000; 26 Suppl 1:87-8. View

Yamazaki H, Oi H, Matsushita M, Tang J, Nose T, Koizumi M . Heparin induces rapid and remarkable elevation of hepatocyte growth factor/scatter factor during trans arterial embolization of renal cell carcinoma. Anticancer Res. 1997; 17(2B):1435-7. View

Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni M . Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging. 2002; 23(4):531-6. DOI: 10.1016/s0197-4580(02)00003-9. View

10.

Buee L, Hof P, Delacourte A . Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci. 1997; 826:7-24. DOI: 10.1111/j.1749-6632.1997.tb48457.x. View

11.

Snow A, Kinsella M, Parks E, Sekiguchi R, Miller J, Kimata K . Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch Biochem Biophys. 1995; 320(1):84-95. DOI: 10.1006/abbi.1995.1345. View

12.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G . Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21(3):383-421. PMC: 3887148. DOI: 10.1016/s0197-4580(00)00124-x. View

13.

Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L . Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-6. DOI: 10.1038/349704a0. View

14.

Barrett A . The many forms and functions of cellular proteinases. Fed Proc. 1980; 39(1):9-14. View

15.

Lomas D, Carrell R . Serpinopathies and the conformational dementias. Nat Rev Genet. 2002; 3(10):759-68. DOI: 10.1038/nrg907. View

16.

Weitz J . Low-molecular-weight heparins. N Engl J Med. 1997; 337(10):688-98. DOI: 10.1056/NEJM199709043371007. View

17.

Buee L, Ding W, Anderson J, Narindrasorasak S, Kisilevsky R, Boyle N . Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide. Brain Res. 1993; 627(2):199-204. DOI: 10.1016/0006-8993(93)90321-d. View

18.

Schlessinger J, Lax I, Lemmon M . Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?. Cell. 1995; 83(3):357-60. DOI: 10.1016/0092-8674(95)90112-4. View

19.

DAndrea M, Nagele R . Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des. 2006; 12(6):677-84. DOI: 10.2174/138161206775474224. View

20.

Yasuhara O, Walker D, McGeer P . Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease. Brain Res. 1994; 654(2):234-40. DOI: 10.1016/0006-8993(94)90484-7. View